Ravoxertinib|1453848-26-4|(GDC-0994)-陌孚医药/Medlife

您当前的位置：

Ravoxertinib (Synonyms: GDC-0994)

目录号: PL04562 纯度: ≥99%

CAS No. :1453848-26-4

商品编号	规格	价格	会员价
PL04562-2mg	2mg	¥1607.00	请登录
PL04562-5mg	5mg	¥2410.00	请登录
PL04562-10mg	10mg	¥4146.00	请登录
PL04562-50mg	50mg	¥12054.00	请登录
PL04562-100mg	100mg	询价	询价
PL04562-200mg	200mg	询价	询价
PL04562-10mM*1mLinDMSO	10mM*1mLinDMSO	¥2338.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Ravoxertinib
中文别名	1-[(1S)-1-(4-氯-3-氟苯基)-2-羟基乙基]-4-[2-[(1-甲基-1H-吡唑-5-基)氨基]-4-嘧啶基]-2(1H)-吡啶酮;GDC-0994 抑制剂;GDC-0994
英文名称	Ravoxertinib
英文别名	GDC-0994;(S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one;GDC0994;Ravoxertinib;R6AXV96CRH;1-[(1~{s})-1-(4-Chloranyl-3-Fluoranyl-Phenyl)-2-Oxidanyl-Ethyl]-4-[2-[(2-Methylpyrazol-3-Yl)amino]pyrimidin-4-Yl]pyridin-2-One;6QB;1-[(1S)-1-(4-CHLORO-3-FLUOROPHENYL)-2-HYDROXYETHYL]-4-{2-[(2-METHYLPYRAZOL-3-YL)AMINO]PYRIMIDIN-4-YL}PYRIDIN-2-ONE;1-[(1S)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-
Cas No.	1453848-26-4
分子式	C₂₁H₁₈ClFN₆O₂
分子量	440.86
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

Ravoxertinib (GDC-0994) 是具有口服活性的 ERK 激酶抑制剂，抑制 ERK1 和 ERK2 的IC₅₀ 分别为6.1 nM 和 3.1 nM。

生物活性

Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with an IC 50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.

性状

Solid

IC50 & Target[1][2]

ERK1 6.1 nM (IC50) ERK2 3.1 nM (IC50

体外研究(In Vitro)

Ravoxertinib (GDC-0994) also inhibits p90RSK with an IC50 of 12 nM.
Ravoxertinib (GDC-0994) is highly selective for ERK1 and ERK2, with biochemical potency of 1.1 nM and 0.3 nM, respectively.
Ravoxertinib (GDC0994; 50 nM, 0.5 μM, and 5 μM; 48 hours) decreases the viability of lung adenocarcinoma cell lines (A549, HCC827, HCC4006). has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

In CD-1 mice, a 10 mg/kg oral dose of Ravoxertinib (GDC-0994) is sufficient to achieve the desired target coverage for at least 8 h. Daily, oral dosing of Ravoxertinib results in significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice. has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Blake JF, et al. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Developme
[2]. Kirk Robarge, et al. Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development. Proceedings: AACR Annual Meeting 2014; April 5-9, 2014.

溶解度数据	In Vitro: DMSO : ≥ 35 mg/mL (79.39 mM)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation